Research Roundup

Debbie Rigby rounds up the latest in research news   Identifying prevalence and risk factors for metformin non-persistence Non-persistence to therapy may be a significant barrier to the use of metformin. Data from this retrospective cohort study show low starting dose of metformin is associated with significantly lower rates of reported side effects and non-persistence.

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Who is leading the way?
Next Pharmacist faces 40 years in prison over sex scandal